Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03768817 · ClinicalTrials.gov registry record
Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program
A clinical trial of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 20
- Enrollment target
- 15
- Study locations
NCT03768817 is a study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 20 participants. The trial reports 15 study locations across 11 states.
The verdict
NCT03768817, a study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigational New Drug (eIND) program.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (15)
California
- Children's Hospital of Los Angeles - Los Angeles
- Kaiser Permanente - Los Angeles
- Children's Hospital of Orange County - Orange
- Stanford University - Palo Alto
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Connecticut
- Yale University - New Haven
District of Columbia
- Children's National Hospital - Washington D.C.
Florida
- University of South Florida - Tampa
Georgia
- Emory University - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- University of Minnesota Masonic Children's Hospital - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2020-06-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03768817
The ClinicalTrials.gov registry entry for NCT03768817 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT03768817 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, Pennsylvania, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03768817 about?
NCT03768817 is a clinical study titled "Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program". The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigational New Drug (eIND) program.
What is the current status of trial NCT03768817?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2019-01-30. Estimated completion is 2020-06-08.
What conditions does trial NCT03768817 study?
This clinical trial studies the following conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD).
What interventions are being tested in trial NCT03768817?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT03768817?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03768817 being conducted?
This trial has 15 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.